Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children.
Phase of Trial: Phase IV
Latest Information Update: 03 Jun 2017
At a glance
- Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; DTaP-hepatitis B-poliovirus vaccine
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 12 Aug 2009 Actual patient number (283) added as reported by ClinicalTrials.gov.
- 08 Jul 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov.